Clinically significant bleeding with ticagrelor vs clopidogrel in Korean patients with acute coronary syndromes intended for invasive management: A randomized clinical trial
Circulation Dec 13, 2019
Park DW, Kwon O, Jang JS, et al. - Among Korean patients (n = 800) hospitalized for acute coronary syndromes with or without ST elevation and reserved for invasive management, researchers assessed clinically significant bleeding at 12 months among those randomly allocated to receive, in a 1:1 ratio, ticagrelor (180 mg loading dose, 90 mg twice daily thereafter) or clopidogrel (600 mg loading dose, 75 mg daily thereafter) in this multicenter trial. Both the treatment groups did not significantly differ in terms of the incidence of death from cardiovascular causes, myocardial infarction, or stroke. A higher incidence of clinically significant bleeding was reported in relation to standard-dose ticagrelor vs clopidogrel treatment in Korean acute coronary syndrome patients intended to receive early invasive management. Exercising caution was recommended while interpreting a numerically higher incidence of ischemic events.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries